Edition:
United States

Adamis Pharmaceuticals Corp (ADMP.OQ)

ADMP.OQ on NASDAQ Stock Exchange Capital Market

3.45USD
1:25pm EST
Change (% chg)

$0.90 (+35.29%)
Prev Close
$2.55
Open
$2.85
Day's High
$3.60
Day's Low
$2.67
Volume
510,793
Avg. Vol
95,744
52-wk High
$6.45
52-wk Low
$2.35

Chart for

About

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's... (more)

Overall

Beta: 0.49
Market Cap(Mil.): $85.14
Shares Outstanding(Mil.): 33.39
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 30.98 16.31
EPS (TTM): -- -- --
ROI: -- 14.12 35.74
ROE: -- 15.72 17.71

BRIEF-Adamis Pharmaceuticals Updates Symjepi Commercialization Plans

* ADAMIS PHARMACEUTICALS UPDATES SYMJEPI COMMERCIALIZATION PLANS

9:12am EST

BRIEF-Adamis Pharmaceuticals Announces FDA Acceptance For Review For The  Supplemental New Drug Application

* ADAMIS PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE FOR REVIEW FOR THE SUPPLEMENTAL NEW DRUG APPLICATION OF ITS LOW DOSE SYMJEPI PRODUCT CANDIDATE

Feb 12 2018

BRIEF-Adamis Pharmaceuticals Subsidiary Develops Compound To Manage Ulcers In Horses

* US COMPOUNDING, A SUBSIDIARY OF ADAMIS PHARMACEUTICALS, DEVELOPS A UNIQUE COMPOUND TO MANAGE ULCERS IN HORSES Source text for Eikon: Further company coverage:

Dec 06 2017

BRIEF-Adamis Pharmaceuticals Announces Submission Of Investigational New Drug (Ind) Application To The FDA

* ADAMIS PHARMACEUTICALS ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO THE FDA FOR NEW PRODUCT CANDIDATE FOR THE TREATMENT OF OPIOID OVERDOSE Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Dec 04 2017

BRIEF-Adamis Pharma Submits Prior Approval Supplement To FDA For The Pediatric Version Of Symjepi

* ADAMIS PHARMACEUTICALS SUBMITS PRIOR APPROVAL SUPPLEMENT TO FDA FOR THE PEDIATRIC VERSION OF SYMJEPI

Nov 29 2017

Competitors

  Price Chg
GlaxoSmithKline plc (GSK.L) 1,296.00 -7.00

Earnings vs. Estimates